Cindunistat
Alternative Names: SC-84250; SD-6010Latest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Class Antirheumatics; Cysteines
- Mechanism of Action Nitric oxide synthase type II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 28 Feb 2012 Discontinued - Phase-II/III for Osteoarthritis in Australia (PO)
- 28 Feb 2012 Discontinued - Phase-II/III for Osteoarthritis in Canada (PO)
- 28 Feb 2012 Discontinued - Phase-II/III for Osteoarthritis in European Union (PO)